Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells

Targeted cancer therapy includes, amongst others, antibody-based delivery of toxic payloads to selectively eliminate tumor cells. This payload can be either a synthetic small molecule drug composing an antibody-drug conjugate (ADC) or a cytotoxic protein composing an immunotoxin (IT). Non-human cyto...

Descripción completa

Detalles Bibliográficos
Autores principales: Jordaan, Sandra, Akinrinmade, Olusiji A., Nachreiner, Thomas, Cremer, Christian, Naran, Krupa, Chetty, Shivan, Barth, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874685/
https://www.ncbi.nlm.nih.gov/pubmed/29510557
http://dx.doi.org/10.3390/biomedicines6010028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874685/
https://www.ncbi.nlm.nih.gov/pubmed/29510557
http://dx.doi.org/10.3390/biomedicines6010028

Ejemplares similares